138 related articles for article (PubMed ID: 30372698)
1. Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
[TBL] [Abstract][Full Text] [Related]
2. Role of HDL cholesterol in anthracycline-induced subclinical cardiotoxicity: a prospective observational study in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ou W; Jiang T; Zhang N; Lu K; Weng Y; Zhou X; Wang D; Dong Q; Tang X
BMJ Open; 2024 Feb; 14(2):e074541. PubMed ID: 38341200
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Buege MJ; Drill E; Horwitz SM; LeVoir A; Pak T; Peterson TJ; Dao PH; Matasar MJ
Eur J Haematol; 2023 Jul; 111(1):96-102. PubMed ID: 36971022
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection of High-Risk Individuals.
Upshaw JN; Mohanty S; Rastogi A
Heart Fail Clin; 2022 Jul; 18(3):385-402. PubMed ID: 35718414
[TBL] [Abstract][Full Text] [Related]
5. Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.
Amadori D
Hematol Rep; 2011 Oct; 3(3s):e1. PubMed ID: 22586509
[TBL] [Abstract][Full Text] [Related]
6. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
[TBL] [Abstract][Full Text] [Related]
7. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.
Liu C; Chen H; Guo S; Liu Q; Chen Z; Huang H; Zhao Q; Li L; Cen H; Jiang Z; Luo Q; Chen X; Zhao J; Chen W; Yang PC; Wang L
Biomed Pharmacother; 2023 Oct; 166():115373. PubMed ID: 37647693
[TBL] [Abstract][Full Text] [Related]
8. The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
Brown SA; Okwuosa TM; Barac A; Volgman AS
J Am Heart Assoc; 2020 Jan; 9(2):e015327. PubMed ID: 31960742
[No Abstract] [Full Text] [Related]
9. Cardiovascular disease in adult survivors of childhood cancer.
Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
[TBL] [Abstract][Full Text] [Related]
10. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.
Bansal N; Adams MJ; Ganatra S; Colan SD; Aggarwal S; Steiner R; Amdani S; Lipshultz ER; Lipshultz SE
Cardiooncology; 2019; 5():18. PubMed ID: 32154024
[TBL] [Abstract][Full Text] [Related]
11. Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma.
Upshaw JN; Nelson J; Sweigart B; Rodday AM; Kumar AJ; Konstam MA; Wong JB; Ky B; Karmiy S; Friedberg JW; Evens AM; Kent DM; Parsons SK
JACC CardioOncol; 2024 Apr; 6(2):200-213. PubMed ID: 38774008
[TBL] [Abstract][Full Text] [Related]
12. Statin Therapy for Prevention of Anthracycline Cardiotoxicity - Another Defeat for Cardioprotection?
Divakaran S; Nohria A
NEJM Evid; 2022 Sep; 1(9):EVIDe2200166. PubMed ID: 38319795
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
Bertorello N; Luksch R; Bisogno G; Haupt R; Spallarossa P; Cenna R; Fagioli F
Pediatr Blood Cancer; 2023 Jun; ():e30515. PubMed ID: 37355856
[TBL] [Abstract][Full Text] [Related]
14. The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin.
Chaulin AM
Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004288
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in the Development of Anthracycline-Associated Heart Failure.
Diaz ANR; Hurtado GP; Manzano AAA; Keyes MJ; Turissini C; Choudhary A; Curtin C; Dommaraju S; Warack S; Strom JB; Asnani A
J Card Fail; 2023 Nov; ():. PubMed ID: 37951494
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies.
Veeder JA; Hothem LN; Cipriani AE; Jensen BC; Rodgers JE
Pharmacotherapy; 2021 Dec; 41(12):1066-1080. PubMed ID: 34806206
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Morbidity and Mortality in Patients with Sarcoma: A Population-Based Study.
Alanazi R; Aljizeeri A; Alsaileek A; Alrashid A; Alolayan A; Alkaiyat M; Alenazy B; Shehata H; Alqahtani J; Ardah H; Alshammari K
Clin Med Insights Oncol; 2024; 18():11795549241237703. PubMed ID: 38558879
[TBL] [Abstract][Full Text] [Related]
18. Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma.
Luminari S; Montanini A; Federico M
Hematol Rep; 2011 Oct; 3(3s):e4. PubMed ID: 22586512
[TBL] [Abstract][Full Text] [Related]
19. An integrated approach to cardioprotection in lymphomas.
Maraldo MV; Levis M; Andreis A; Armenian S; Bates J; Brady J; Ghigo A; Lyon AR; Manisty C; Ricardi U; Aznar MC; Filippi AR
Lancet Haematol; 2022 Jun; 9(6):e445-e454. PubMed ID: 35512725
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
